Individual Study / DOORWAY

Determinants Of Oral corticosteroid Responsiveness in Wheezing Asthmatic Youth

Determinants Of Oral corticosteroid Responsiveness in Wheezing Asthmatic Youth

DOORWAY logo
Networks -
Datasets -
Variables -
Start Year
2011
End Year
2013
Visit DOORWAY

Members

Download
Investigators Contacts
  • Dr. Francine Ducharme
    Sainte-Justine University Health Centre
  • Roger (CHEO) Zemek
    Children’s Hospital of Eastern Ontario
  • Jocelyn Gravel
    Sainte-Justine University Hospital
  • Dominique Chalut
    Montreal Children's Hospital
  • Naveen Poonai
    London Health Sciences Centre
  • Sophie Laberge
    Sainte-Justine University Hospital
  • Caroline Quach
    Montreal Children's Hospital
  • Maja Krajinovic
    Sainte-Justine University Hospital
  • Chantal Guimont
    Centre Hospitalier Universitaire Laval
  • Catherine Lemière
    Hôpital Sacré-Coeur
  • Marie-Claude Guertin
    Montreal Health Innovations Coordination Centre
  • Anna Smyrnova
    CHU Sainte-Justine

Design

Study design
Cohort
Follow Up

10  days follow up to gather information on asthma control, quality of life and 10 day follow up for revisit of emergency department.

Supplementary Information

Parents, legal guardians or care giver were allowed to respond several CRFs in the study.

Marker Paper

Ducharme F, et al. Determinants Of Oral corticosteroid Responsiveness in Wheezing Asthmatic Youth (DOORWAY): protocol for a prospective multicentre cohort study of children with acute moderate-to-severe asthma exacerbations. BMJ Open 2014;4:e004699

PUBMED 24710133

Recruitment

Recruitment Target
  • Individuals

Number of Participants

Number of Participants
975
Number of Participants with Biological Samples
968
Supplementary Information

From 975 enrolled patients:

Patients provided DNA samples: 906 samples

Patients provided Cotinine samples: 930 samples

Patients provided nasopharyngeal samples: 968 samples

Patients provided sputum samples: 11 samples

Access

Availability of data and biosamples

Possible Access to Data
Possible Access to Biosamples
Other

Timeline

Children with acute asthma

Selection Criteria
Minimum age
1
Maximum age
17
Newborns
Twins
Countries
  • Canada
Territory

Montreal, Quebec, Ottawa and London

Ethnic Origin
Health Status
  • Moderate to severe asthma exacerbation
Other Criteria

Participants were eligible if they: (1) were aged 1–17 years; (2) had asthma, defined as: (i) prior diagnosis of asthma made by a physician; (ii) prior documented episode of acute cough, wheezing and/or dyspnoea with significant response to inhaled β2-agonists or to oral corticosteroids; (iii) in a child aged <2 years, three or more episodes of cough, wheezing and/or dyspnoea, including the index visit or (iv) previous lung function tests showing significant reversibility postbronchodilation (≥12% FEV1 or ≥25% Rrs at 4–8 Hz) or a positive provocation test (PC20 ≤8 mg/mL or provocation dose (to increase Rrs by 50% or more (PD50) ≤8 mg/mL), in keeping with the American Thoracic Society and European Respiratory Society criteria; (3) presented with an acute episode of cough, wheezing and/or dyspnoea; (4) had moderate-to-severe airway obstruction, defined as a PRAM score >3 at baseline; (5) had a good understanding of English or French and (6) were accompanied by parents or legal guardians.

 

Patients were excluded if they presented: (1) with another chronic respiratory condition (such as bronchopulmonary dysplasia or cystic fibrosis); (2) with a reasonable suspicion of bronchiolitis or foreign body aspiration; (3) a history of hypersensitivity to salbutamol, ipratropium bromide or oral prednisolone; (4) a relative or absolute contraindication to receiving oral corticosteroids such as recent exposure to varicella or live vaccine in a susceptible child or (5) with confirmed or suspected pregnancy status.

Recruitment

Sources of recruitment
  • Specific population
Specific Population
  • Other specific population :

    Children visiting emergency department with an asthma exacerbation.

Participants from Existing Studies

Number of Participants

Number of Participants
975
Number of Participants with Biological Samples
968
Supplementary Information about selection criteria

From 975 enrolled patients:

Patients provided DNA samples: 906 samples

Patients provided Cotinine samples: 930 samples

Patients provided nasopharyngeal samples: 968 samples

Patients provided sputum samples: 11 samples

Data Collection Events
# Name Description Start End
0 Index ED visit

Index ED visit (Baseline): demographics, treatment given, lung function assessment, determinants of response, PRAM scores, medications (current asthma, non-asthma and ...

2011-02 2013-12
1 10-day follow up period

10-day follow up period: Patient functional status measured daily on the ‘Asthma flare-up Diary for young children©’, use of rescue and controller medications documented on a ...

2011-02 2014-01

Classifications

Socio-demographic and economic characteristics
Lifestyle and behaviours
Birth, pregnancy and reproductive health history
Perception of health, quality of life, development and functional limitations
Diseases
Symptoms and signs
Medication and supplements
Non-pharmacological interventions
Health and community care services utilization
Death
Physical measures and assessments
Laboratory measures
Cognition, personality and psychological measures and assessments
Life events, life plans, beliefs and values
Preschool, school and work life
Social environment and relationships
Physical environment
Administrative information

Socio-demographic and economic characteristics

Age/birthdate
Sex/gender
Ethnicity, race and religion
Language
Labour force and retirement
Income, possessions, and benefits

Lifestyle and behaviours

Tobacco
Drugs

Perception of health, quality of life, development and functional limitations

Functional limitations

Diseases

Certain infectious and parasitic diseases (A00-B99)
Diseases of the ear and mastoid process (H60-H95)
Diseases of the circulatory system (I00-I99)
Diseases of the respiratory system (J00-J99)
Injury, poisoning and certain other consequences of external causes (S00-T98)
Diseases without precise specification or falling into multiple categories

Symptoms and signs

Symptoms and signs involving the circulatory and respiratory systems (R00-R09)
Symptoms and signs involving the digestive system and abdomen (R10-R19)
Symptoms and signs involving the skin and subcutaneous tissue (R20-R23)
General symptoms and signs (R50-R69)
Symptoms related to multiple categories

Medication and supplements

Medication and supplement intake
Posology and protocol of administration

Non-pharmacological interventions

Physical therapy interventions
Educational and health promotion interventions
Laboratory diagnosis interventions
Other and unspecified non-pharmacological interventions

Health and community care services utilization

Visits to health professionals
Hospitalizations
Other health and community care

Death

Vital status
Other end of life or death-related information

Physical measures and assessments

Anthropometry
Circulation and respiration

Laboratory measures

Hematology
Biochemistry
Microbiology
Virology
Genomics

Physical environment

Chemical exposure
Biological exposure
Other physical environment characteristics

Administrative information

Identifiers
Date and time-related information
Questionnaire and interview-related information
Physical and cognitive measure and biosample-related information
Data and sample collection center-related information
Other administrative information